Navigation Links
Chiasma's Octreolin™ (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects

NEW YORK and JERUSALEM, June 6, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate. Most important, the data illustrated that Octreolin reduced growth hormone (GH) levels, a clinical endpoint that has been used for approval in other drugs for acromegaly.

Chiasma is developing Octreolin as an oral treatment for acromegaly and anticipates that a Phase 3 trial in patients will begin enrollment later in 2011.

Pharmacodynamic data presented at the Congress demonstrated that a single dose of Octreolin administered to healthy subjects significantly suppressed both basal GH secretion and Growth Hormone Releasing Hormone (GHRH)-stimulated GH secretion by about 80%. Inhibition was recorded in all 18 subjects receiving Octreolin as compared to their GH levels without Octreolin. The mean reductions in both basal and stimulated GH levels were statistically significant (P<0.001).

In addition, the presentation summarized results from three clinical studies with Octreolin. These data showed that:

  • Octreolin was absorbed after oral administration within 1 hour;
  • There was a reproducible linear dose-dependent relationship for the 3 doses studied;
  • An oral dose of Octreolin 20 mg provided similar systemic exposure to octreotide 0.1 mg given via subcutaneous (SC) injection;
  • The drug was well tolerated with no significant clinical or preclinical adverse events;
  • Side effects of Octreolin were comparable to those of injectable octreotide.

Octreolin utilizes the Company's proprietary Transient Permeability Enhancer (TPE) technology, which enables previously injectable-only drugs to be taken orally.

Sam Teichman, MD, Chiasma's Chief Medical Officer and presenter at the Congress said, "In addition to the GH reducing effect observed in the trial conducted in the United States under an Investigational New Drug (IND), no significant Octreolin or TPE-related adverse findings were reported in two toxicology studies in primates and, therefore, the No Adverse Event Level (NOAEL) was established at the highest Octreolin dose tested. This clean safety profile paves the way for further Octreolin development with chronic therapy in patients and continues the validation of the safety profile of the underlying technology platform.

"If the results of the Phase 3 program are positive, the Company intends to submit a New Dug Application (NDA) using the 505(b)(2) NDA regulatory pathway in the U.S. and its European Medicines Agency (EMA) equivalent, the Hybrid Application, in Europe."

How Octreolin Works

Octreolin is a product in capsule form that contains octreotide acetate, a 1.0 kDa peptide and the Company's proprietary TPE technology. The TPE system allows its drug cargo to cross mucosal epithelia in the small intestine by inducing a temporary opening of the Tight Junctions that seal and regulate passage (the paracellular route) between cells. This effect on the epithelia is rapid and fully reversible. The drug reaches the bloodstream effectively in its native active form.

TPE activity is the result of a proprietary combination of excipients assembled in a process leading to a suspension of hydrophilic particles in a lipophilic medium. Chiasma has developed a unique, simple and cost effective production process that seeks to maximize safety and stability of its drug products; all components used in manufacturing of the drug product are approved for pharmaceutical use. The TPE technology is versatile, can be applied to a wide range of therapeutic agents and requires no chemical modification of the drug.

About Acromegaly

Acromegaly is an endocrine condition associated with a benign adenoma in the pituitary gland that secretes excess GH, which stimulates excess production of insulin-like growth factor 1 (IGF-1) by the liver, causing tissue growth throughout the body. Even well-controlled patients have an increased risk for mortality; and in poorly controlled patients, cardiovascular, respiratory, endocrine, and metabolic morbidities result in standardized mortality ratios of 2.5 when compared to nonacromegaly populations.(1)

Injectable (subcutaneous and intramuscular) somatostatin analogs, which bind to somatostatin receptors (SSTR2, SSTR5) to inhibit GH secretion are the therapeutic standard of care for acromegaly patients who are not cured by resection of the tumor; surgery is the first line of treatment. GH inhibition by octreotide, the most commonly used somatostatin analog in clinical use, reduces or reverses morbidity and mortality associated with acromegaly. There is a well-defined correlation between plasma levels of octreotide and reduction in GH and IGF-1 levels. Clinical endpoints include suppression of GH and normalization of IGF-1 levels.(2)

Treatment with Sandostatin LAR® (depot formulation of octreotide acetate), a monthly IM injection, is the most common treatment of choice for life. Octreotide is effective for 95% of the patients; approximately 65% and 30% of patients show a complete or partial response, respectively. However, the injections cause discomfort and pain, with 30% to 50% of patients reporting pain at the injection site (for doses of 20 mg and 30 mg Sandostatin LAR). Patients can also suffer from welts that take a considerable period of time to disappear. In addition, patient needle-phobia can manifest itself in non-compliance as well as stress and anxiety for those who ultimately do take the injections. Furthermore, the octreotide longacting injections require complex reconstitution and caregivers' assistance, frequently necessitating visits to physician offices.

The pool of acromegaly patients eligible for Octreolin treatment is estimated to be approximately 15,000 in the U.S. and an equal number in Europe.

About Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being converted from injectable to oral, but importantly can result in the development of new indications. The Company's TPE technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection and can be utilized also with small molecules that are already orally available but are poorly absorbed.

Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary.

Additional information can be found at:

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

(1) Melmed et al., Guidelines for Acromegaly Management, J Clin Endocrinol Metab, May 2009, 94(5):1509-1517

(2) Sandostatin, octreotide acetate, Injection, Rx Only, Prescribing Information

SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
3. MIMcloud 2.0, the Next Generation of Cloud Computing for Medical Images, Shown at SIIM 2011
4. Use of a Simple Three-Step Process and Prevention Algorithm to Protect Skin Shown to Reduce Pressure Ulcers
5. Caldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
6. Slo-Niacin® Dietary Supplement Shown to Support Good Cholesterol (HDL)
7. Tocotrienols Shown to be Effective in Lowering Fat Levels in Blood
8. Luminex MAGPIX System Shown to be More Cost Effective and Efficient Than Conventional ELISA Method in Initial Study
9. VSL#3® Probiotic Shown Effective in Dietary Management of Children With Irritable Bowel Syndrome
10. SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days
11. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Post Your Comments:
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... locations throughout Arkansas that offers insurance and financial preparation services, is providing an ... Rock City Rescue organization. , Rock City Rescue is a locally recognized nonprofit ...
(Date:10/13/2017)... ... 2017 , ... The International Association of Eating Disorders Professionals ... the field of eating disorders, announces the opening of early registration for the ... at the Omni Resort at ChampionsGate. , The annual iaedp™ Symposium ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
Breaking Medicine News(10 mins):